BIVI Projected Dividend Yield

Cl A (New)/BioVie Inc ( NASDAQ : BIVI )

BioVie is a clinical-stage company developing drug therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, Co.'s orphan drug candidate, BIV201 (continuous infusion terlipressin), is being developed as a future treatment option for patients suffering from ascites and other life-threatening complications of liver cirrhosis caused by nonalcoholic steatohepatitis, hepatitis, and alcoholism. In neurodegenerative disease, Co.'s product candidate, NE3107, is an orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance and primary pathological inflammatory cascades with a mechanism of action.

20 YEAR PERFORMANCE RESULTS